Information de reference pour ce titreAccession Number: | 00000605-201601190-00003.
|
Author: | He, Tianhua MD; Li, Kan MS; Roberts, Mark S. MD, MPP; Spaulding, Anne C. MD, MPH; Ayer, Turgay PhD; Grefenstette, John J. PhD; Chhatwal, Jagpreet PhD
|
Institution: | From the University of Pittsburgh, Pittsburgh, Pennsylvania; Tsinghua University School of Medicine, Beijing, China; University of Texas Health Science Center at Houston, Houston, Texas; Rollins School of Public Health, Emory University, and H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia; and Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.
|
Title: | |
Source: | Annals of Internal Medicine. 164(2):84-92, January 19, 2016.
|
Abstract: | Background: The prevalence of hepatitis C virus (HCV) in U.S. prisoners is high; however, HCV testing and treatment are rare. Infected inmates released back into society contribute to the spread of HCV in the general population. Routine hepatitis screening of inmates followed by new therapies may reduce ongoing HCV transmission.
Objective: To evaluate the health and economic effect of HCV screening and treatment in prisons on the HCV epidemic in society.
Design: Agent-based microsimulation model of HCV transmission and progression of HCV disease.
Data Sources: Published literature.
Target Population: Population in U.S. prisons and general community.
Time Horizon: 30 years.
Perspective: Societal.
Interventions: Risk-based and universal opt-out hepatitis C screening in prisons, followed by treatment in a portion of patients.
Outcome Measures: Prevention of HCV transmission and associated disease in prisons and society, costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), and total prison budget.
Results of Base-Case Analysis: Implementing risk-based and opt-out screening could diagnose 41 900 to 122 700 new HCV cases in prisons in the next 30 years. Compared with no screening, these scenarios could prevent 5500 to 12 700 new HCV infections caused by released inmates, wherein about 90% of averted infections would have occurred outside of prisons. Screening could also prevent 4200 to 11 700 liver-related deaths. The ICERs of screening scenarios were $19 600 to $29 200 per QALY, and the respective first-year prison budget was $900 to $1150 million. Prisons would require an additional 12.4% of their current health care budget to implement such interventions.
Results of Sensitivity Analysis: Results were sensitive to the time horizon, and ICERs otherwise remained less than $50 000 per QALY.
Limitation: Data on transmission network, reinfection rate, and opt-out HCV screening rate are lacking.
Conclusion: Universal opt-out HCV screening in prisons is highly cost-effective and would reduce HCV transmission and HCV-associated diseases primarily in the outside community. Investing in U.S. prisons to manage hepatitis C is a strategic approach to address the current epidemic.
Primary Funding Source: National Institutes of Health.
(C) 2016 American College of Physicians
|
References: | 1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. [PMID: 24737271] doi:10.7326/M13-1133
2. Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129:187-95. [PMID: 24587554]
3. Spaulding AC, Seals RM, McCallum VA, Perez SD, Brzozowski AK, Steenland NK. Prisoner survival inside and outside of the institution: implications for health-care planning. Am J Epidemiol. 2011;173:479-87. [PMID: 21239522]
4. Ginder S, Noonan M. Mortality in local jails and state prisons, 2000-2011: statistical tables. Bureau of Justice Statistics Statistical Tables, 2013; NCJ 242186.
5. Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health. 2015;105:e51-7. [PMID: 25790417]
6. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429-38. [PMID: 21696309]
7. Hughes TA, Wilson DJ. Reentry trends in the United States. U.S. Department of Justice, Bureau of Justice Statistics; 2003. Accessed at www.bjs.gov/content/pub/pdf/reentry.pdf on 25 August 2015.
8. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144:762-9. [PMID: 16702592]
9. Harrison PM, Beck AJ. Prisoners in 2002. U.S. Department of Justice, Bureau of Justice Statistics; 2003. Accessed at www.ncjrs.gov/App/abstractdb/AbstractDBDetails.aspx?id=200248 on 25 August 2015.
10. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014;370:1871-4. [PMID: 24827032]
11. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3. [PMID: 23943776]
12. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-57. [PMID: 23798026] doi:10.7326/0003-4819-159-5-201309030-00672
13. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239]
14. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. [PMID: 21696307]
15. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-28. [PMID: 21696308]
16. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161:546-53. [PMID: 25329202] doi:10.7326/M14-0602
17. Moorjani H, Koenigsmann C, Kim MJ, Spaulding AC. Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012 [Letter]. Emerg Infect Dis. 2015;21:186-8. [PMID: 25531029]
18. Beck AJ, Maruschak LM. Hepatitis testing and treatment in state prisons. U.S. Department of Justice, Office of Justice Programs; 2004. Accessed at www.ncjrs.gov/App/abstractdb/AbstractDBDetails.aspx?id=199173 on 25 August 2015.
19. Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making. 2004;24:20-9. [PMID: 15005951]
20. Graham CS. Hepatitis C and HIV co-infection: closing the gaps [Editorial]. JAMA. 2015;313:1217-8. [PMID: 25705993]
21. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406. [PMID: 25775312] doi:10.7326/M14-1336
22. West HC. Prison inmates at midyear 2009-statistical tables. Bureau of Justice Statistics Statistical Tables. 2010; NCJ 230113. Accessed at www.bjs.gov/content/pub/pdf/pim09st.pdf on 26 August 2015.
23. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170-80. [PMID: 25089861] doi:10.7326/M14-0095
24. Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al; Trent HCV Study Group. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol. 2006;59:144-52. [PMID: 16426949]
25. Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci U S A. 2002;99 Suppl 3:7280-7. [PMID: 12011407]
26. Macal CM, North MJ. Tutorial on agent-based modelling and simulation. Journal of Simulation. 2010;4:151-62.
27. Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2015. Accessed at www.hcvguidelines.org/full-report-view on 7 May 2015.
28. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58:928-36. [PMID: 24399087]
29. Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol. 2010;24:717-26. [PMID: 21165379]
30. Silverman E. What the 'shocking' Gilead discounts on its hepatitis C drugs will mean. The Wall Street Journal. 4 February 2015. Accessed at http://blogs.wsj.com/pharmalot/2...- ouverture dans une nouvelle fenêtre on 4 February 2015.
31. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8. [PMID: 8849754]
32. James N. The Bureau of Prisons (BOP): operations and budget. Congressional Research Service. 4 March 2014. Accessed at www.fas.org/sgp/crs/misc/R42486.pdf on 27 August 2015.
33. Kyckelhahn T. State corrections expenditures, FY 1982-2010. Bureau of Justice Statistics. December 2012; NCJ 239672. Accessed at www.bjs.gov/content/pub/pdf/scefy8210.pdf on 27 August 2015.
34. Chhatwal J, He T. Economic evaluations with agent-based modelling: an introduction. Pharmacoeconomics. 2015;33:423-33. [PMID: 25609398]
35. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32. [PMID: 22895429]
36. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-70. [PMID: 22056542] doi:10.7326/0003-4819-156-4-201202210-00378
37. Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health. 2014;104:e69-74. [PMID: 24825235]
38. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59:1411-9. [PMID: 25114031]
39. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013;56:1382-93. [PMID: 23392392]
40. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55:1344-55. [PMID: 22135116]
41. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One. 2013;8:e58975. [PMID: 23533595]
42. Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013;21:27-35. [PMID: 23596276]
43. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47:952-61. [PMID: 18715156] doi:10.1086/591707
|
Language: | English.
|
Document Type: | Original Research.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0003-4819
|
NLM Journal Code: | 0372351, 5a6
|
Annotation(s) | |
|
|